Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.

MLA

Nathan, Steven D., et al. “Riociguat for Idiopathic Interstitial Pneumonia-Associated Pulmonary Hypertension (RISE-IIP): A Randomised, Placebo-Controlled Phase 2b Study.” Lancet Respiratory Medicine, vol. 7, no. 9, Sept. 2019, pp. 780–90. EBSCOhost, https://doi.org/10.1016/S2213-2600(19)30250-4.

APA

Nathan, S. D., Behr, J., Collard, H. R., Cottin, V., Hoeper, M. M., Martinez, F. J., Corte, T. J., Keogh, A. M., Leuchte, H., Mogulkoc, N., Ulrich, S., Wuyts, W. A., Yao, Z., Boateng, F., & Wells, A. U. (2019). Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine, 7(9), 780–790. https://doi.org/10.1016/S2213-2600(19)30250-4

Chicago

Nathan, Steven D, Jürgen Behr, Harold R Collard, Vincent Cottin, Marius M Hoeper, Fernando J Martinez, Tamera J Corte, et al. 2019. “Riociguat for Idiopathic Interstitial Pneumonia-Associated Pulmonary Hypertension (RISE-IIP): A Randomised, Placebo-Controlled Phase 2b Study.” Lancet Respiratory Medicine 7 (9): 780–90. doi:10.1016/S2213-2600(19)30250-4.